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Introduction: Selection of first line treatment for patients with metastatic colorectal
cancer (mCRC) is based on tumour and patient related factors. The wide and
increasingly use of targeting agents in this setting are proven to be beneficial in first
line treatment. Increasing evidence suggests that this first line treatment is of great
importance and its impact is being studied in prospective studies. In this retrospective
analysis, we aimed to analyze the first treatment used and its potential impact on
overall survival (OS).
Methods: Retrospective study of patients diagnosed and treated in our institution with
metastatic colorectal cancer between January 2009 and December 2014. Specific filters
of search were applied as patients with metastatic adenocarcinoma with unresectable
disease having chemotherapy and confirmed death certificate. The clinicopathologic
features as age, gender, tumor histologic type, first treatment administered and time
between diagnosis and death were assessed. Treatment was stratified and divided into 4
categories: 1) Infusional 5-FU; 2) FOLFIRI; 3) FOLFOX-4; 4) CT plus targeted therapy.
Data was analyzed using IBM SPSS v22.
Results:We evaluated 137 patients (48 women and 89 men) with a median age at
diagnosis of 65 years (38-86). Primary tumor localization was the rectum (21.7%),
sigmoid (19.7%), right colon (29.9%) and left colon (29.2%). First line treatment with
chemotherapy (CT) Infusional 5-FU represented 27%, FOLFIRI 24.1%, FOLFOX-4
29.9% and CT plus targeted therapy 19%. Median OS in the CT plus targeted therapy
group was 24.7 months (95% CI 7.8-41.6) followed by FOLFOX-4 with 24.5 months
(95% CI 16.2-32.8), FOLFIRI with 17.5 months (95% CI 11.2-23.9) and Infusional
5-FU group with 14.7 months (95% CI 4.9-24.5). Overall comparison between each
treatment were not statistically significant (log rank = 0,159). There was no statistically
difference in subgroup analysis by age.
Conclusion: Patients with mCRC are having increasingly improved overall survivals
with many of the treatments available. In this small study, no statistical difference
was found between the four main options used in first line treatment of mCRC and
survival. Upfront use of targeted therapy represented a small portion of the patients
in our center (19%). Some limitations of this study were that further lines of therapy
and changes in resectability status of lesions were not assessed. More prospective
studies are needed to define the ideal first line therapy and the best timing for each
therapy.
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